These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 25893544

  • 1. Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome.
    Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Doyle RT, Philip S, Soni PN, Juliano RA.
    Metab Syndr Relat Disord; 2015 Aug; 13(6):239-47. PubMed ID: 25893544
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.
    Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN.
    Cardiovasc Diabetol; 2013 Jul 09; 12():100. PubMed ID: 23835245
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides.
    Vijayaraghavan K, Szerlip HM, Ballantyne CM, Bays HE, Philip S, Doyle RT, Juliano RA, Granowitz C.
    Postgrad Med; 2019 Aug 09; 131(6):390-396. PubMed ID: 31306043
    [Abstract] [Full Text] [Related]

  • 6. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
    Ballantyne CM, Bays HE, Philip S, Doyle RT, Braeckman RA, Stirtan WG, Soni PN, Juliano RA.
    Atherosclerosis; 2016 Oct 09; 253():81-87. PubMed ID: 27596132
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
    Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN.
    Am J Cardiol; 2012 Oct 01; 110(7):984-92. PubMed ID: 22819432
    [Abstract] [Full Text] [Related]

  • 9. Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials).
    Mosca L, Ballantyne CM, Bays HE, Guyton JR, Philip S, Doyle RT, Juliano RA.
    Am J Cardiol; 2017 Feb 01; 119(3):397-403. PubMed ID: 27939227
    [Abstract] [Full Text] [Related]

  • 10. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
    Brinton EA, Ballantyne CM, Guyton JR, Philip S, Doyle RT, Juliano RA, Mosca L.
    J Womens Health (Larchmt); 2018 Sep 01; 27(9):1170-1176. PubMed ID: 29583081
    [Abstract] [Full Text] [Related]

  • 11. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).
    Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN.
    Am J Cardiol; 2011 Sep 01; 108(5):682-90. PubMed ID: 21683321
    [Abstract] [Full Text] [Related]

  • 12. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies.
    Ballantyne CM, Bays HE, Braeckman RA, Philip S, Stirtan WG, Doyle RT, Soni PN, Juliano RA.
    J Clin Lipidol; 2016 Sep 01; 10(3):635-645.e1. PubMed ID: 27206952
    [Abstract] [Full Text] [Related]

  • 13. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study).
    Ballantyne CM, Braeckman RA, Bays HE, Kastelein JJ, Otvos JD, Stirtan WG, Doyle RT, Soni PN, Juliano RA.
    J Clin Lipidol; 2015 Sep 01; 9(3):377-83. PubMed ID: 26073397
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
    Kedia AW, Lynch E.
    Postgrad Med; 2015 Sep 01; 127(8):869-73. PubMed ID: 26453247
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
    Chapman MJ, Zamorano JL, Parhofer KG.
    Pharmacol Ther; 2022 Sep 01; 237():108172. PubMed ID: 35304222
    [Abstract] [Full Text] [Related]

  • 20. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results.
    Budoff MJ, Muhlestein JB, Bhatt DL, Le Pa VT, May HT, Shaikh K, Shekar C, Kinninger A, Lakshmanan S, Roy SK, Tayek J, Nelson JR.
    Cardiovasc Res; 2021 Mar 21; 117(4):1070-1077. PubMed ID: 32609331
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.